Factor exposure
Growth tilted with a strong quality bias.
H143 Research Intelligence
Research before
conviction.
A systematic framework for separating narrative from durable compounding—combining growth, financial health, expectations and valuation.
Independent publicationPrimary-source researchNo client accounts or outside capital
Our research methodology →
Editorial standard
Research begins with issuer filings, earnings materials and clearly identified assumptions. Conclusions remain open to revision when the evidence, valuation or risk profile changes.
Research intelligence
Growth × financial health
Lower healthFinancial healthHigher health
GrowthValue
Growth-ledBalancedValue-led
RBRKRubrik
01 / 13A−MetricAssessmentSignal
Directional H143 research signals—not live financial data or price targets. Refresh after filings and material guidance changes.
Research insights
Evidence over narrative
Earnings revisions
Track estimate direction after every reported quarter.
Valuation discipline
Test the thesis across multiples, DCF and downside cases.
Research philosophy
Growth, disciplined by financial reality.
H143 studies durable growth where balance-sheet strength, improving economics and a rational valuation may create a credible path to long-term compounding.
Business quality
Competitive position, customer retention, pricing power and management execution.
Financial health
Liquidity, leverage, EBITDA quality, free cash flow and dilution discipline.
Expectations
Revenue and earnings revisions, guidance credibility and catalyst visibility.
Valuation
PEG, P/E, PVG composite, DCF, book value and EV/EBITDA where applicable.
Research universe
Companies under research.
A working set of businesses used to test the research framework across industries, growth profiles and valuation conditions. Inclusion does not indicate ownership or a recommendation.
Company assessments
Scoring methodology
A matrix designed to be challenged.
Each company is assessed on consistent evidence. Scores are qualitative research inputs—not forecasts—and should be refreshed after earnings, guidance changes or material company events.
Growth
Revenue runway, market expansion, backlog, retention and operating leverage.
Financial health
Cash, leverage, free cash flow, EBITDA quality, dilution and capital intensity.
Expectations
Consensus revisions, guidance, estimate dispersion and catalyst timing.
Valuation
PEG, P/E, PVG composite, DCF, book value per share and EV/EBITDA.
Data standard
Financial statements and company guidance should come from the latest issuer filings and earnings materials. Analyst expectations and valuation inputs should be timestamped and sourced before public display. Biotech and pre-profit companies require pipeline-adjusted measures because conventional P/E or EBITDA may not be meaningful.
Research journal
Ideas in progress.
Company notes, watchlist research and long-term perspectives—organized in a dedicated research journal.
RESEARCH NOTE 01 · NASDAQ: FLY
Firefly Aerospace
Contract momentum, lunar execution and the risks embedded in an ambitious space platform.
Read research note →WATCHLIST BRIEF 01 · NYSE: ROLRollins, Inc.
Durable essential-services compounder under active review after a material valuation reset.
Read complete brief →RESEARCH PERSPECTIVEMarket observations
Long-term perspectives on valuation, cycles and business quality.
Open observations →